SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an ...
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in ...
Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making ...
Zacks Investment Research on MSN
AstraZeneca (AZN) dips more than broader market: What you should know
Astrazeneca (AZN) closed at $183.60 in the latest trading session, marking a -2.82% move from the prior day. The stock ...
French biotech Abivax has been the subject of intense takeover speculation for months. But a spokesperson denied a report by ...
British pharma major AstraZeneca (LSE: AZN) is stepping up its China strategy with plans to build a commercial cell therapy ...
The EU approval of Imfinzi for early-stage gastric and gastroesophageal cancers expands the label of one of the company’s top ...
AstraZeneca, a global, science-led biopharmaceutical company, has made available its treatment, Soliris®, in Malaysia as part ...
As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice. | As AstraZeneca ...
AstraZeneca said on Thursday it would build a cell therapy manufacturing and supply base and an innovation centre in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results